Trial *
Publication Winchester S, J Infect (2021) (published paper)

Funding: Private (SaNOtize Research & Development Corporation, Canada, through Metanoic Health Ltd., UK.)
Conflict of interest: *

Methods
RCT
Location : Single center / UK
Follow-up duration (days): 18
Inclusion criteria
  • Adults (18–70 years) who were isolated with mild COVID-19 infection confirmed by laboratory SARS-CoV-2 RT-PCR nasal and throat swab within the 48 h of randomisation
Exclusion criteria NR
Interventions
Treatment
NONS
4 sprays (each 120–140μL of solution) nasally 5-6 times a day for 9 days.
Control
Placebo

Participants
Randomized
participants :
NONS=40
Placebo=40
Characteristics of participants
N= 80
Mean age : NR
29 males
Severity : Mild: n= 80/ Asymptomatic: n=14
Number of vaccinated participants: NR
Primary outcome
In the register
NR
In the report
NR
Documents
available

Protocol

NR

Statistical plan

NR

Data-sharing willing stated in the publication:

Not reported
Risk of bias
Overall
The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review
Some concerns
General comment Only the published article was used in data extraction and assessment of risk of bias. No registry, protocol or statistical analysis plan was available. This was a small clinical trial reported only in a brief letter.